Weight Loss Pharmacotherapy : Current and Future Therapies - 12/09/24

Doi : 10.1016/j.giec.2024.06.006

Gabriela Jordan, MD ^a,^b, Sigrid Young, MD ^a,^b, José O. Alemán, MD, PhD ^a,^b,^c,^⁎
^a Department of Medicine, Margaret Corbin Campus of the VA New York Harbor Health Care System, New York, NY, USA
^b Laboratory of Translational Obesity Research, NYU Langone Health, New York, NY, USA
^c Holman Division of Endocrinology, New York University Langone Health, 423 East 23rd Street, Room 16-048W, New York, NY 10010, USA

^∗Corresponding author. Holman Division of Endocrinology, New York University Langone Health, 423 East 23rd Street, Room 16-048W, New York, NY 10010.Holman Division of EndocrinologyNew York University Langone Health423 East 23rd Street, Room 16-048WNew YorkNY10010

Résumé

The rising prevalence of obesity is of major concern. There are currently 5 Food and Drug Administration-approved medications for the treatment of obesity: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3.0 mg, and semaglutide 2.4 mg. Surgical options such as bariatric surgery and endoscopic surgery induce more durable weight loss than pharmacotherapy or lifestyle interventions alone. However, patients often experience weight regain and weight loss plateau after surgery. The addition of multimodal or multihormonal pharmacotherapy is a promising tool to address these challenges. The optimal timing of obesity pharmacotherapy with surgical and endoscopic interventions requires further investigation.

Le texte complet de cet article est disponible en PDF.

Keywords : Obesity, Pharmacotherapy, GLP-1 agonist, Weight loss, Bariatric surgery, Endoscopic bariatric surgery